Healthcare Industry News: Tryton Medical
News Release - December 19, 2013
Tryton Medical Establishes Bifurcation InstituteDURHAM, N.C.--(Healthcare Sales & Marketing Network)--Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, today announced the launch of the Bifurcation Institute. The Bifurcation Institute is a comprehensive education resource established to advance the standard of care for bifurcated coronary artery disease, a common, and often untreated, clinical need.
Membership in the Bifurcation Institute is free and provides physicians access to e-newsletters summarizing recent clinical data and news, links to timely webcasts and a Case Library that highlights the latest techniques and tips when treating bifurcation disease. Clinical symposia and educational workshops will be offered through the Bifurcation Institute.
"There is a significant unmet need for education and training regarding bifurcations. In patients undergoing PCI-stenting, approximately one-third has a bifurcation lesion. Left main disease, an accumulation of plaque that narrows the base of the coronary tree, is a persistent challenge in interventional cardiology, as more than 75 percent of left main lesions are bifurcation lesions. The Bifurcation Institute aims to evolve treatment patterns and current procedural guidance to incorporate safe and effective treatment of bifurcations in daily practice," said Dr. Maciej Lesiak, who is chief of the catheterization laboratory at the Karol Marcinkowski University of Medical Sciences in Poznan, Poland. On March 5-6, 2014, Dr. Lesiak and his institution will host the inaugural Bifurcation Institute workshop focusing on the clinical outcomes and treatment of bifurcation lesions with the Tryton Side Branch Stent.
The Bifurcation Institute features the results of the landmark Tryton IDE trial presented in a late-breaking clinical trial session at TCT 2013.
"Tryton Medical is pleased to offer the Bifurcation Institute, which expands our commitment to physician education and training worldwide," said Shawn McCarthy, CEO of Tryton Medical. "It is our intent that the Bifurcation Institute will become the preferred resource for physicians providing evidence-based care to patients with complex bifurcation disease.”
About Coronary Bifurcation Disease
Coronary artery disease often results in the buildup of plaque at the site of a bifurcation, where one artery branches from another. Current approaches to treating these lesions are time consuming and technically difficult. As a result, the side branch is often left unstented, leaving it vulnerable to higher rates of restenosis, the re-narrowing of the stented vessel following implantation.
About Tryton Medical, Inc.
Tryton Medical, Inc., located in Durham, N.C., is the leading developer of novel stent systems for the treatment of bifurcation lesions. The company was founded in 2003 by Aaron V. Kaplan, M.D. (professor of medicine at Dartmouth Medical School/Dartmouth- Hitchcock Medical Center) and Dan Cole, General Partner at Spray Ventures. Privately held, Tryton is backed by PTV Sciences, RiverVest Venture Partners, Spray Venture Partners, and the 3x5 Special Opportunity Fund. For more information please visit www.trytonmedical.com and follow the company on Twitter at @TrytonMedical1.
Source: Tryton Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.